Impacts of probiotics on the efficacies of immune checkpoint inhibitors with or without chemotherapy for patients with advanced non‐small‐cell lung cancer

Documenti analoghi

• TGF ‐β Inhibitor Potentiates Osimertinib‐Induced Anti‐Tumor Immunity in Egfr ‐Mutant Lung Cancer
  di: Tadahiro Kuribayashi, et al.
  Pubblicazione: (2026)
• Concomitant osimertinib and antituberculosis therapy in an elderly patient with EGFR‐mutated lung cancer and pulmonary tuberculosis: A case report
  di: Hiroaki Matsuura, et al.
  Pubblicazione: (2024)
• Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr ‐mutated lung cancer
  di: Jun Nishimura, et al.
  Pubblicazione: (2026)
• Chromosome segregation errors during early embryonic development
  di: Hirohisa Kyogoku
  Pubblicazione: (2025)
• Efficacy of immune checkpoint inhibitors according to programmed cell death‐ligand 1 expression in patients with non‐small cell lung cancer and brain metastasis: A real‐world prospective observational study
  di: Takeshi Masuda, et al.
  Pubblicazione: (2024)